Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Intercept Pharmaceuticals Inc (NASDAQ: ICPT)  concerning whether a series of statements by Intercept Pharmaceuticals Inc  regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company's treatment for primary biliary cholangitis ("PBC"), advising them that the drug has been tied to liver injuries and death among patients suffering from PBC.

On September 21, 2017, the FDA issued a Safety Announcement that the drug “is being incorrectly dosed in some patients…resulting in an increased risk of serious liver injury and death.” Per the FDA “In the 13 months after Ocaliva was approved in May 2016, FDA received reports of serious liver injury or death associated with Ocaliva.”

On this news, NASDAQ: ICPT has fallen, causing investors harm.

Based in New York, New York, and founded in 2002 Intercept Pharmaceuticals Inc is a biopharmaceutical company, focusing on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.

If you purchased shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) on or before September 12, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185